Stock SBLOF SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Shin Nippon Biomedical Laboratories, Ltd. OTC Markets

Equities

SBLOF

JP3379950003

Market Closed - OTC Markets
Other stock markets
 11:58:04 2023-05-16 EDT 		5-day change 1st Jan Change
16.97 USD -.--% Intraday chart for Shin Nippon Biomedical Laboratories, Ltd. -.--% -.--%
05-08 Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Forecasts for the Six Months Ending September 30, 2024 and Year Ending March 31, 2025 CI
02-02 Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024 CI

Strengths

  • The company returns high margins, thereby supporting business profitability.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. Stock Shin Nippon Biomedical Laboratories, Ltd.
-.--% 369M -
MODERNA, INC. Stock Moderna, Inc.
+16.59% 45.51B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-9.89% 38.52B
B
LONZA GROUP AG Stock Lonza Group AG
+38.08% 38.13B
A
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+27.12% 30.74B
B
CELLTRION, INC. Stock Celltrion, Inc.
-8.64% 26.03B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.81% 25.92B
B-
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+45.08% 14.13B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.85% 12.73B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.19% 11.29B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2395 Stock
  4. SBLOF Stock
  5. Ratings Shin Nippon Biomedical Laboratories, Ltd.